Dapagliflozin: drug profile and its role in individualized treatment.
Dapagliflozin is the first sodium-glucose co-transporter inhibitor developed. An extensive program covering all phases of clinical research showed us the efficacy and safety profile of the drug. Dapagliflozin and the other SGLT2 inhibitors are a new treatment alternative in patients with Type 2 diabetes either as monotherapy or combined with the hypoglycemic agents currently available and is approved in approximately 38 countries worldwide. This drug profile provides the necessary tools to assess the risks and benefits of this new molecule.